Table 1.
Clinical Characteristics of the Glioma Primary Cohort with Known IDH1/1p-19q Status
| Primary Glioma (n = 74) Feature | IDH-mut Non-Codel (n = 54) | IDH-mut Codel (n = 7) | IDH-WT (n = 13) |
|---|---|---|---|
|
| |||
| Clinical | |||
|
| |||
| Cohort (n, %) | |||
|
| |||
| TCGA | 13(24.07%) | 3 (42.86%) | 13(100%) |
| Non-TCGA | 41 (75.93%) | 4(57.14%) | 0 (0%) |
|
| |||
| 2016 WHO (n, %) | |||
|
| |||
| Oligodendroglioma grade II | 0 (0%) | 4(57.14%) | 0 (0%) |
| Astrocytoma grade II | 47 (87.04%) | 0 (0%) | 0 (0%) |
| Anaplastic oligodendroglioma grade III | 0 (0%) | 3 (42.86%) | 2(15.38%) |
| Anaplastic astrocytoma grade III | 6(11.11%) | 0 (0%) | 0 (0%) |
| Glioblastoma grade IV | 1 (1.85%) | 0 (0%) | 11 (84.62%) |
|
| |||
| Gender (n, %) | |||
|
| |||
| Female | 22 (40.74%) | 3 (42.86%) | 5 (38.46%) |
| Male | 32 (59.26%) | 4(57.14%) | 8 (61.54%) |
|
| |||
| Age (n, %) | |||
|
| |||
| ≤ 40 years | 41 (75.93%) | 2 (28.57%) | 3 (23.08%) |
| > 40 years | 13(24.07%) | 5 (71.43%) | 10(76.92%) |
|
| |||
| Treatment | |||
|
| |||
| Radiation after Surgery (n, %) | |||
|
| |||
| Yes | 18(33.33%) | 3 (42.86%) | 13(100%) |
| No | 36 (66.67%) | 4(57.14%) | 0 (0%) |
|
| |||
| Adjuvant TMZ | |||
|
| |||
| Yes | 11 (20.37%) | 1 (14.29%) | 6(46.15%) |
| No | 40 (74.07%) | 6(85.71%) | 5 (38.46%) |
| Unknown | 3 (5.56%) | 0 (0%) | 2(15.38%) |
Percentages were calculated as a proportion of a total amount of tumor samples in the glioma primary cohort with known IDH1/1p-19q status by group. In cases where more than one tumor fragment per primary surgery were investigated, each case was counted once to avoid overrepresentation of data.